The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Recent Trends in Noninvasive Tests for Assessing Hepatic Fibrosis in Patients with Chronic Liver Disease

만성 간질환 환자의 간섬유화 평가를 위한 비침습적 검사의 최근 동향

  • Jung Hwan Yu (Division of Gastroenterology, Department of Internal Medicine, Inha University College of Medicine)
  • 유정환 (인하대학교 의과대학 소화기내과학교실)
  • Received : 2024.08.28
  • Accepted : 2024.09.25
  • Published : 2024.10.01
Download PDF
⟨ Previous Next ⟩

Abstract

Hepatic fibrosis is a critical factor in predicting hepatocellular carcinoma occurrence and prognosis in patients with liver disease, making its accurate assessment essential for managing chronic liver disease. Traditionally, liver biopsy has been the standard method for evaluating hepatic fibrosis. However, due to its invasive nature and the limitation of sampling only a small portion of the liver, it is not suitable for widespread use in chronic liver disease patients. Recently, there has been growing interest in noninvasive tests for assessing hepatic fibrosis, including imaging techniques and serum biomarkers. These noninvasive tests are being continuously developed and are increasingly being utilized to evaluate the prognosis of chronic liver disease patients and to inform clinical practice. This paper reviews the recent trends in noninvasive methods for assessing hepatic fibrosis in patients with chronic liver disease, based on studies published to date.

Keywords

References

  1. Kim MN, Han JW, An J, et al. KASL clinical practice guidelines for noninvasive tests to assess liver fibrosis in chronic liver disease. Clin Mol Hepatol 2024;30 Suppl:S5-S105.
  2. Rosenberg WM, Voelker M, Thiel R, et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004;127:1704-1713.
  3. Anstee QM, Castera L, Loomba R. Impact of non-invasive biomarkers on hepatology practice: past, present and future. J Hepatol 2022;76:1362-1378.
  4. Lee Y, Bae S, Kim JH, et al. Diagnostic efficacy of serum asialo α1-acid glycoprotein levels for advanced liver fibrosis and cirrhosis in patients with chronic hepatitis B compared to that in healthy subjects: a prospective study. J Clin Med 2023;12:712.
  5. Lee EY, Kang JH, Kim KA, et al. Development of a rapid, immunochromatographic strip test for serum asialo alpha1-acid glycoprotein in patients with hepatic disease. J Immunol Methods 2006;308:116-123.
  6. Williams AL, Hoofnagle JH. Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Relationship to cirrhosis. Gastroenterology 1988;95:734-739.
  7. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38:518-526.
  8. Harrison SA, Oliver D, Arnold HL, Gogia S, Neuschwander-Tetri BA. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 2008;57:1441-1447.
  9. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006;43:1317-1325.
  10. Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007;45:846-854.
  11. Harrison SA, Ratziu V, Boursier J, et al. A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol 2020;5:970-985.
  12. Narimatsu H. Development of M2BPGi: a novel fibrosis serum glyco-biomarker for chronic hepatitis/cirrhosis diagnostics. Expert Rev Proteomics 2015;12:683-693.
  13. Shirabe K, Bekki Y, Gantumur D, et al. Mac-2 binding protein glycan isomer (M2BPGi) is a new serum biomarker for assessing liver fibrosis: more than a biomarker of liver fibrosis. J Gastroenterol 2018;53:819-826.
  14. Daniels SJ, Leeming DJ, Eslam M, et al. ADAPT: an algorithm incorporating PRO-C3 accurately identifies patients with NAFLD and advanced fibrosis. Hepatology 2019;69:1075-1086.
  15. Boyle M, Tiniakos D, Schattenberg JM, et al. Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease. JHEP Rep 2019;1:188-198.
  16. Guha IN, Parkes J, Roderick P, et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 2008;47:455-460.
  17. Kim SU, Kim JK, Park JY, et al. Variability in liver stiffness values from different intercostal spaces. Liver Int 2009;29:760-766.
  18. Boursier J, Konate A, Guilluy M, et al. Learning curve and interobserver reproducibility evaluation of liver stiffness measurement by transient elastography. Eur J Gastroenterol Hepatol 2008;20:693-701.
  19. Bercoff J, Tanter M, Fink M. Supersonic shear imaging: a new technique for soft tissue elasticity mapping. IEEE Trans Ultrason Ferroelectr Freq Control 2004;51:396-409.
  20. Bamber J, Cosgrove D, Dietrich CF, et al. EFSUMB guidelines and recommendations on the clinical use of ultrasound elastography. Part 1: basic principles and technology. Ultraschall Med 2013;34:169-184.
  21. Zhang YN, Fowler KJ, Ozturk A, et al. Liver fibrosis imaging: a clinical review of ultrasound and magnetic resonance elastography. J Magn Reson Imaging 2020;51:25-42.
  22. Bureau C, Metivier S, Peron JM, et al. Transient elastography accurately predicts presence of significant portal hypertension in patients with chronic liver disease. Aliment Pharmacol Ther 2008;27:1261-1268.
  23. Robic MA, Procopet B, Metivier S, et al. Liver stiffness accurately predicts portal hypertension related complications in patients with chronic liver disease: a prospective study. J Hepatol 2011;55:1017-1024.
  24. Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines for management of chronic hepatitis B. Clin Mol Hepatol 2022;28:276-331.
  25. Poynard T, de Ledinghen V, Zarski JP, et al. Relative performances of FibroTest, Fibroscan, and biopsy for the assessment of the stage of liver fibrosis in patients with chronic hepatitis C: a step toward the truth in the absence of a gold standard. J Hepatol 2012;56:541-548.
  26. Imbert-Bismut F, Ratziu V, Pieroni L, et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001;357:1069-1075.
  27. Voican CS, Louvet A, Trabut JB, et al. Transient elastography alone and in combination with FibroTest® for the diagnosis of hepatic fibrosis in alcoholic liver disease. Liver Int 2017;37:1697-1705.
  28. Thiele M, Madsen BS, Hansen JF, Detlefsen S, Antonsen S, Krag A. Accuracy of the enhanced liver fibrosis test vs FibroTest, elastography, and indirect markers in detection of advanced fibrosis in patients with alcoholic liver disease. Gastroenterology 2018;154:1369-1379.
  29. Sheptulina A, Shirokova E, Nekrasova T, Blum H, Ivashkin V. Platelet count to spleen diameter ratio non-invasively identifies severe fibrosis and cirrhosis in patients with autoimmune hepatitis. J Gastroenterol Hepatol 2016;31:1956-1962.
  30. Corpechot C, Gaouar F, El Naggar A, et al. Baseline values and changes in liver stiffness measured by transient elastography are associated with severity of fibrosis and outcomes of patients with primary sclerosing cholangitis. Gastroenterology 2014;146:970-979; quiz e15-e16.
  31. Ehlken H, Wroblewski R, Corpechot C, et al. Validation of transient elastography and comparison with spleen length measurement for staging of fibrosis and clinical prognosis in primary sclerosing cholangitis. PLoS One 2016;11:e0164224.
  32. Suh B, Park S, Shin DW, et al. High liver fibrosis index FIB-4 is highly predictive of hepatocellular carcinoma in chronic hepatitis B carriers. Hepatology 2015;61:1261-1268.
  33. Jeong J, Shin JW, Jung SW, Lee SB, Park EJ, Park NH. Clinical usefulness of noninvasive fibrosis indices for predicting hepatocellular carcinoma in treatment-naive patients with chronic hepatitis B following entecavir therapy. Hepatol Res 2021;51:923-932.
  34. Jeon MY, Lee HW, Kim SU, et al. Subcirrhotic liver stiffness by FibroScan correlates with lower risk of hepatocellular carcinoma in patients with HBV-related cirrhosis. Hepatol Int 2017;11:268-276.
  35. Kim MN, An J, Kim EH, et al. Transient elastography for significant fibrosis in treatment-naive CHB patients: a systematic review and meta-analysis. Clin Mol Hepatol 2024;30 Suppl:S106-S116.
  36. Yu JH, Han JW, Suh YJ, et al. Assessment of the postoperative prognosis in patients with hepatocellular carcinoma using transient elastography: a systemic review and meta-analysis. Clin Mol Hepatol 2024;30 Suppl:S186-S198.
  37. Singh S, Fujii LL, Murad MH, et al. Liver stiffness is associated with risk of decompensation, liver cancer, and death in patients with chronic liver diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2013;11:1573-1584.e1-e2;quiz e88-e89.
  38. Seo YG, Polyzos SA, Park KH, Mantzoros CS. Fibrosis-4 index predicts long-term all-cause, cardiovascular and liver-related mortality in the adult Korean population. Clin Gastroenterol Hepatol 2023;21:3322-3335.
  39. Sohn W, Chang Y, Cho YK, Hong YS, Shin H, Ryu S. Liver fibrosis scores and risk of liver-related mortality in young adults with chronic hepatitis B: a cohort study. J Viral Hepat 2022;29:69-77.
  40. Zhang Y, Wang R, Yang X. FIB-4 index serves as a noninvasive prognostic biomarker in patients with hepatocellular carcinoma: a meta-analysis. Medicine (Baltimore) 2018;97:e13696.
  41. Petta S, Sebastiani G, Vigano M, et al. Monitoring occurrence of liver-related events and survival by transient elastography in patients with nonalcoholic fatty liver disease and compensated advanced chronic liver disease. Clin Gastroenterol Hepatol 2021;19:806-815.e5.
  42. You MW, Kim KW, Pyo J, et al. A meta-analysis for the diagnostic performance of transient elastography for clinically significant portal hypertension. Ultrasound Med Biol 2017;43:59-68.
  43. Berzigotti A. Non-invasive evaluation of portal hypertension using ultrasound elastography. J Hepatol 2017;67:399-411.
  44. Shi KQ, Fan YC, Pan ZZ, et al. Transient elastography: a meta-analysis of diagnostic accuracy in evaluation of portal hypertension in chronic liver disease. Liver Int 2013;33:62-71.
  45. Maurice JB, Brodkin E, Arnold F, et al. Validation of the baveno VI criteria to identify low risk cirrhotic patients not requiring endoscopic surveillance for varices. J Hepatol 2016;65:899-905.
  46. Marot A, Trepo E, Doerig C, Schoepfer A, Moreno C, Deltenre P. Liver stiffness and platelet count for identifying patients with compensated liver disease at low risk of variceal bleeding. Liver Int 2017;37:707-716.
  47. European Association for the Study of the Liver; Clinical Practice Guideline Panel; EASL Governing Board representative. EASL clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update. J Hepatol 2021;75:659-689.
  48. Yu JH, Lee HA, Kim SU. Noninvasive imaging biomarkers for liver fibrosis in nonalcoholic fatty liver disease: current and future. Clin Mol Hepatol 2023;29 Suppl:S136-S149.